title: [Clinical outcome and analysis of radical prostatectomy in clinical stage B and C prostate cancer].
abstract: Between 1989 and 1999, 40 patients treated with radical prostatectomy for clinical stage B and C prostate cancer were analyzed. Prostate-specific antigen (PSA) failure after radical prostatectomy occurred in four patients, and one of them died of clinical recurrence of prostate cancer. Cause-specific survival at 5 years was 91.7% and PSA failure-free rate at 5 years was 76.8%. Staging accuracy of CT and MRI image was not satisfactory. In 41.7% patients, extracapsular extension can not be determined. Preoperative serum PSA levels of pathologically organ-confined disease (OCD) patients were significantly lower than those of pathologically non-OCD patients. Further analysis indicated that preoperative serum PSA levels of greater than 20.1 ng/ml are useful predictors for pathologically non-OCD.
authors.affiliation: Department of Urology, Yokohama City University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: H
authors.initials: H
authors.lastname: Uemura
authors.forename: K
authors.initials: K
authors.lastname: Mikata
authors.forename: H
authors.initials: H
authors.lastname: Ohuchi
authors.forename: S
authors.initials: S
authors.lastname: Jinza
authors.forename: M
authors.initials: M
authors.lastname: Yao
authors.forename: M
authors.initials: M
authors.lastname: Takeda
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: K
authors.initials: K
authors.lastname: Noguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
mesh_terms: D000368:Aged; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome